Back to the Top
Dear All,
It would be great if responses to Prasad's question below could also
be posted on the forum, not withstanding any private mails to Prasad.
Implementing 6.0 will require validation again and time to familiarize
with it, so it would be good to get a feel of what one gains by the
switch.
Thank you all,
Frieda
Pharmacokineticist
Kendle, Clinical Pharmacology Unit
Back to the Top
The following message was posted to: PharmPK
Dear All,
Perhaps a colleague from Pharsight could tell us, whether and how
the core non-compartmental computation routines and the linear
mixed effects routines were changed (e.g. untouched, minor /
major code revision, new features added, ported to another
language, entirely rewritten etc.) in Phoenix 6.0.
Real-life validation issues may or may not come from the core
computation routines (they are maybe more likely to come from
special cases in the dataset; I did not validate Phoenix yet).
Pharsight most likely sells a set of validation examples.
All the best
Juergen
--
Jurgen Bulitta, Ph.D., Senior Scientist
Ordway Research Institute, Albany, NY
Back to the Top
The following message was posted to: PharmPK
Dear All,
As the Pharsight website says, there were a couple of webinars held
last week towards introduction of their new product, Phoenix 6.0.
Right now, only the introductory webinar (held on Jun 11) is available
in the website
http://www.pharsight.com/events/eventsonline_schedule.php
You can download the same after registering. FAQs about Phoenix 6.0 is
available at
http://www.pharsight.com/library/Phoenix_WinNonlin_FAQ.pdf
The webinar comparing both the WinNonlin 5.0 & Phoenix 6.0 (held on 16
July) is not available in the website. Once uploaded, hope it will
answer all our questions.
Habeeb
GVK BIO
Hyderbad, India
Back to the Top
The following message was posted to: PharmPK
Dear All,
In response to Juergen and others regarding validation of WinNonlin 6,
I wanted to share with you some information. First, there were no
changes made to the NCA, LINMIX or modeling engines except for the
following:
* NCA - depending on the observations in the response profile,
WinNonlin 5 would occasionally include Tmax in the times used for
estimation of lambda_z. This cannot happen with the default algorithm
in WinNonlin 6. The computational engines are otherwise unchanged.
* Modeling - some of the models in the PD library were reparameterized
to bring them up to date with current terminology. The engines are
unchanged.
Other than these two items, results generated with WinNonlin 6 will be
identical to those generated with WinNonlin 5.
There are, however, a number of enhancements in Version 6, including
new numerical modeling engines which were not available in WinNonlin
5, workflows, improved plot and table generation, etc. A discussion
of these enhancements can be found on the Pharsight website.
Dan
--
Daniel Weiner, PhD
SrVP & CTO
Pharsight- A Certara(tm) Company
5625 Dillard Dr., Suite 205
Cary, NC 27518
Email: dweiner.aaa.pharsight.com
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "WinNonlin 5.2 and Phoenix 6.0 comparison" as the subject | Support PharmPK by using the |
Copyright 1995-2011 David W. A. Bourne (david@boomer.org)